Market Cap 13.84B
Revenue (ttm) 14.74B
Net Income (ttm) -634.20M
EPS (ttm) N/A
PE Ratio 5.15
Forward PE 5.20
Profit Margin -4.30%
Debt to Equity Ratio 1.07
Volume 4,236,400
Avg Vol 8,742,682
Day's Range N/A - N/A
Shares Out 1.15B
Stochastic %K 77%
Beta 0.84
Analysts Sell
Price Target $12.47

Company Profile

Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 724 514 1800
Address:
Robert J. Coury Global Center, 1000 Mylan Boulevard, Canonsburg, United States
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 24 at 3:54 PM
$VTRS RSI: 89.70, MACD: 0.4305 Vol: 0.56, MA20: 11.38, MA50: 10.75 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
1 · Reply
T_L808
T_L808 Dec. 22 at 9:15 PM
$VTRS decade VWAP applied, stdv bands have barely expanded in 5 years. Pretty good washout early this year then moved right back into VWAP. Looking good here.
0 · Reply
DavyDaveCharts
DavyDaveCharts Dec. 21 at 12:51 PM
$VTRS a pull back to low 11's likely fuels a rally to take out 13's.
1 · Reply
TalkMarkets
TalkMarkets Dec. 19 at 6:32 PM
Stock Analysis - #Viatris $VTRS https://talkmarkets.com/content/stocks--equities/stock-analysis-viatris?post=545848
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 19 at 4:16 PM
Actionable Trade Alert for $VTRS: Market Context: $VTRS is currently trading at $11.94, near its 60D high of $12.03, indicating bullish momentum. The RSI at 84.15 suggests that the stock is overbought, which may lead to a pullback, but the strong upward trend cannot be ignored. Directional Bias: The stock is above its 30-day MA of $10.90 and 50-day MA of $10.64, indicating a bullish trend. The proximity to the 60D high reinforces a potential breakout, but caution is warranted due to the high RSI. Trade Plan: - Suggested Entry: $11.94 - Stop Loss: $11.50 (risking $0.44) - Take Profit Targets: 1. TP1: $12.10 (1.34% gain) 2. TP2: $12.50 (4.69% gain) 3. TP3: $13.95 (16.76% gain) With a potential ROI of 16.76% on TP3, this trade offers a favorable risk-reward ratio. Monitor RSI for signs of reversal. https://privateprofiteers.com
0 · Reply
tanner12oz
tanner12oz Dec. 19 at 3:37 PM
$VTRS this is quietly up 20% the past 3 months..
0 · Reply
bklynlou
bklynlou Dec. 18 at 10:53 PM
$VTRS 12. So close …
1 · Reply
Quantumup
Quantumup Dec. 18 at 2:21 PM
Citizens🏁 $NSRX at a Market Outperform/$19 $SPRY $AQST $VTRS $TEVA AMRX Citizens said in its note: We initiate coverage on Nasus Pharma with a Market Outperform rating and $19 risk-adjusted, DCF-derived price target. Nasus leverages its proprietary Nasax platform to develop dry powder-based intranasal therapies for emergency medical conditions. Its lead candidate, NS002, is a nasal spray formulation of epinephrine currently in Phase 2 development, with the potential to reach the U.S. market by mid-2028. We believe the opportunity for needle-free alternatives to epinephrine autoinjectors (i.e., EpiPen) is large and compelling, and that the introduction of multiple needle-free alternatives will drive a majority market share in coming years. Based on the initial clinical results, we believe NS002 has the potential to be the best-in-class nasal spray epinephrine. Furthermore, we see broad potential for the dry powder technology to drive a pipeline of best-in-class intranasal therapies.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 17 at 3:03 AM
Actionable Trade Alert for $VTRS: Market Context: $VTRS is currently trading at $11.46, showing strong momentum with an RSI of 80.41, indicating overbought conditions. The stock is above its 30-day moving average (MA30) of $10.82 and 50-day moving average (MA50) of $10.57, suggesting bullish sentiment. Directional Bias: The high of $11.83 over the last 60 days indicates potential resistance, while the low of $9.43 provides a solid support level. The current price is near the upper end of this range, which may lead to profit-taking. Trade Plan: - Suggested Entry: $11.50 - Stop Loss: $11.00 (risking $0.50) - Take Profit Targets: 1. $12.00 (4.35% ROI) 2. $12.50 (8.93% ROI) 3. $13.50 (17.74% ROI) This plan allows for a solid risk-reward ratio, with the potential for a 17% ROI on the third target. Monitor the RSI and price action closely for any signs of reversal. https://privateprofiteers.com
0 · Reply
Con1er_Tucker
Con1er_Tucker Dec. 16 at 4:34 PM
$VTRS SBFM debt around ~$0.85M while cash is ~$9M… clean setup 💰
0 · Reply
Latest News on VTRS
Viatris to Participate in Upcoming Investor Conferences

Nov 24, 2025, 8:00 AM EST - 4 weeks ago

Viatris to Participate in Upcoming Investor Conferences


Viatris Inc. (VTRS) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 2:46 PM EST - 6 weeks ago

Viatris Inc. (VTRS) Q3 2025 Earnings Call Transcript


Viatris Announces Quarterly Dividend

Nov 4, 2025, 6:59 AM EST - 7 weeks ago

Viatris Announces Quarterly Dividend


Viatris: Indore Plant Could Boost 2026 Numbers

Sep 25, 2025, 1:16 PM EDT - 3 months ago

Viatris: Indore Plant Could Boost 2026 Numbers


Viatris Inc. (VTRS) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 11:02 AM EDT - 4 months ago

Viatris Inc. (VTRS) Q2 2025 Earnings Call Transcript


Viatris Hits Snag In Eye Drug Study—Phase 3 Plans Under Review

Jul 18, 2025, 2:17 PM EDT - 5 months ago

Viatris Hits Snag In Eye Drug Study—Phase 3 Plans Under Review


Viatris eye therapy fails to meet late-stage trial goal

Jul 18, 2025, 7:07 AM EDT - 5 months ago

Viatris eye therapy fails to meet late-stage trial goal


Viatris: A Contrarian Bet With Virtually No Downside

Jul 16, 2025, 3:19 AM EDT - 5 months ago

Viatris: A Contrarian Bet With Virtually No Downside


OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 24 at 3:54 PM
$VTRS RSI: 89.70, MACD: 0.4305 Vol: 0.56, MA20: 11.38, MA50: 10.75 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
1 · Reply
T_L808
T_L808 Dec. 22 at 9:15 PM
$VTRS decade VWAP applied, stdv bands have barely expanded in 5 years. Pretty good washout early this year then moved right back into VWAP. Looking good here.
0 · Reply
DavyDaveCharts
DavyDaveCharts Dec. 21 at 12:51 PM
$VTRS a pull back to low 11's likely fuels a rally to take out 13's.
1 · Reply
TalkMarkets
TalkMarkets Dec. 19 at 6:32 PM
Stock Analysis - #Viatris $VTRS https://talkmarkets.com/content/stocks--equities/stock-analysis-viatris?post=545848
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 19 at 4:16 PM
Actionable Trade Alert for $VTRS: Market Context: $VTRS is currently trading at $11.94, near its 60D high of $12.03, indicating bullish momentum. The RSI at 84.15 suggests that the stock is overbought, which may lead to a pullback, but the strong upward trend cannot be ignored. Directional Bias: The stock is above its 30-day MA of $10.90 and 50-day MA of $10.64, indicating a bullish trend. The proximity to the 60D high reinforces a potential breakout, but caution is warranted due to the high RSI. Trade Plan: - Suggested Entry: $11.94 - Stop Loss: $11.50 (risking $0.44) - Take Profit Targets: 1. TP1: $12.10 (1.34% gain) 2. TP2: $12.50 (4.69% gain) 3. TP3: $13.95 (16.76% gain) With a potential ROI of 16.76% on TP3, this trade offers a favorable risk-reward ratio. Monitor RSI for signs of reversal. https://privateprofiteers.com
0 · Reply
tanner12oz
tanner12oz Dec. 19 at 3:37 PM
$VTRS this is quietly up 20% the past 3 months..
0 · Reply
bklynlou
bklynlou Dec. 18 at 10:53 PM
$VTRS 12. So close …
1 · Reply
Quantumup
Quantumup Dec. 18 at 2:21 PM
Citizens🏁 $NSRX at a Market Outperform/$19 $SPRY $AQST $VTRS $TEVA AMRX Citizens said in its note: We initiate coverage on Nasus Pharma with a Market Outperform rating and $19 risk-adjusted, DCF-derived price target. Nasus leverages its proprietary Nasax platform to develop dry powder-based intranasal therapies for emergency medical conditions. Its lead candidate, NS002, is a nasal spray formulation of epinephrine currently in Phase 2 development, with the potential to reach the U.S. market by mid-2028. We believe the opportunity for needle-free alternatives to epinephrine autoinjectors (i.e., EpiPen) is large and compelling, and that the introduction of multiple needle-free alternatives will drive a majority market share in coming years. Based on the initial clinical results, we believe NS002 has the potential to be the best-in-class nasal spray epinephrine. Furthermore, we see broad potential for the dry powder technology to drive a pipeline of best-in-class intranasal therapies.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 17 at 3:03 AM
Actionable Trade Alert for $VTRS: Market Context: $VTRS is currently trading at $11.46, showing strong momentum with an RSI of 80.41, indicating overbought conditions. The stock is above its 30-day moving average (MA30) of $10.82 and 50-day moving average (MA50) of $10.57, suggesting bullish sentiment. Directional Bias: The high of $11.83 over the last 60 days indicates potential resistance, while the low of $9.43 provides a solid support level. The current price is near the upper end of this range, which may lead to profit-taking. Trade Plan: - Suggested Entry: $11.50 - Stop Loss: $11.00 (risking $0.50) - Take Profit Targets: 1. $12.00 (4.35% ROI) 2. $12.50 (8.93% ROI) 3. $13.50 (17.74% ROI) This plan allows for a solid risk-reward ratio, with the potential for a 17% ROI on the third target. Monitor the RSI and price action closely for any signs of reversal. https://privateprofiteers.com
0 · Reply
Con1er_Tucker
Con1er_Tucker Dec. 16 at 4:34 PM
$VTRS SBFM debt around ~$0.85M while cash is ~$9M… clean setup 💰
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 15 at 6:36 AM
Actionable Trade Alert for $VTRS: Market Context: $VTRS is currently trading at $11.65, exhibiting strong momentum with an RSI of 92.81, indicating overbought conditions. The stock is approaching its 60D high of $11.72, suggesting potential resistance. The moving averages (MA30 at $10.75 and MA50 at $10.51) indicate a bullish trend, as the price is above both MAs. Directional Bias: Given the high RSI and proximity to the 60D high, caution is warranted. However, if momentum persists, a breakout could occur. Trade Plan: - Suggested Entry: $11.65 - Stop Loss: $11.30 (3% below entry) - Take Profit Targets: - TP1: $12.00 (3% gain) - TP2: $12.50 (7.3% gain) - TP3: $13.50 (15% gain) This plan aims for a potential ROI of over 17% with TP3. Monitor closely for signs of reversal as the stock approaches resistance levels. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
ShirleyG
ShirleyG Dec. 13 at 8:02 PM
$VTRS Let's goooo 🔥 🚀 ⬆️ 🤑🆙️📈⏫️⏫️⏫️
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 11 at 11:30 PM
Actionable Trade Alert for $VTRS: Market Context: $VTRS is currently trading at $11.52, showing strong momentum with an RSI of 89.55, indicating overbought conditions. The stock is above its 30-day moving average (MA30) of 10.7 and 50-day moving average (MA50) of 10.48, suggesting bullish sentiment. The 60-day high of $11.63 is just above the current price, providing a potential resistance level. Directional Bias: The high RSI indicates a potential pullback, but the proximity to the 60D high suggests a continuation could occur if momentum persists. Trade Plan: - Suggested Entry: $11.52 - Stop Loss: $10.90 (5.4% below entry) - Take Profit Targets: 1. $11.80 (2.4% gain) 2. $12.00 (4.2% gain) 3. $13.50 (17% gain) Monitor RSI for signs of reversal and adjust targets accordingly. Maintain discipline with stop loss to protect capital. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 11 at 12:53 PM
$VTRS RSI: 81.92, MACD: 0.2447 Vol: 0.33, MA20: 10.72, MA50: 10.36 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
SPYmyQQQ
SPYmyQQQ Dec. 10 at 11:33 PM
🎯 Target Hit 🏁 📨 From Nov 11, 2025 🏛️ $VTRS 💵 Entry: $11.2000 ✅ Exit: $11.5270 💰 P/L: +2.92% 👉 FREE TRIAL! spymyqqq/join/
0 · Reply
ShirleyG
ShirleyG Dec. 10 at 4:32 AM
$VTRS Let's gooo $12🔥🚀🔥
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 10 at 3:33 AM
Actionable Trade Alert for $VTRS: Market Context: $VTRS closed at $11.19, showing a strong upward momentum with an RSI of 64.12, indicating it's nearing overbought territory but still has room to run. The stock is above its 30-day MA of $10.61 and 50-day MA of $10.42, suggesting a bullish trend. Directional Bias: The recent high of $11.32 indicates resistance, while the low of $9.43 provides a solid support level. The current price is close to the 60D high, which may attract profit-taking, but overall momentum remains positive. Trade Plan: - Suggested Entry: $11.20 - Stop Loss: $10.80 (3.6% risk) - Take Profit Targets: - Target 1: $11.50 (2.68% gain) - Target 2: $11.80 (5.24% gain) - Target 3: $13.10 (17% gain) With a favorable risk-reward ratio, this trade setup aims for significant upside potential while managing risk effectively. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
JarvisFlow
JarvisFlow Dec. 9 at 4:27 PM
Barclays has adjusted their stance on Viatris ( $VTRS ), setting the rating to Overweight with a target price of 15.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 8 at 11:21 PM
Actionable Trade Alert for $VTRS: Market Context: $VTRS is currently trading at $11.23, showing bullish momentum as it approaches its 60D high of $11.29. The RSI of 65.92 suggests that the stock is nearing overbought territory, indicating potential for a pullback or continuation of the upward trend. Directional Bias: The stock is above both the 30-day (MA30=10.59) and 50-day (MA50=10.39) moving averages, signaling a strong bullish trend. However, the RSI indicates caution as it approaches overbought levels. Trade Plan: - Suggested Entry: $11.23 - Stop Loss: $10.90 (3% below entry) - Take Profit Targets: - Target 1: $11.50 (2.4% gain) - Target 2: $11.75 (4.6% gain) - Target 3: $13.15 (17% gain) This plan offers a potential 17% ROI on the third target, with a manageable risk. Monitor the stock closely as it approaches the targets. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
Broview
Broview Dec. 7 at 12:02 AM
$VTRS with potential to double the dividend but please focus on pay down the debt?
1 · Reply
ShirleyG
ShirleyG Dec. 6 at 10:23 PM
$VTRS $12🚀🔥 we're getting there!!!
0 · Reply
AlertsAndNews
AlertsAndNews Dec. 6 at 9:44 PM
$VTRS Viatris Announces Agreement to Monetize its Equity Stake in Biocon Biologics Limited "Viatris to Receive $400 Million in Cash and $415 Million in Equity Shares of Biocon Limited"
0 · Reply